Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Tirzepatide

Mounjaro, Zepbound, LY3298176

Quick Stats
Studies 183
Trials 100
Score 3
2025 pubmed

The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review.

Liu. Zhao Z; Yu. Shanshan S; Jin. Xinyan X; Sheng. Luguang L; YanMu. Mai Re MR; Gao. Jie J; Lu. Jun J; Lei. Tao T

Key Findings

  • GLP‑1 receptor agonists improve insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite, leading to better diabetes control and weight loss.
  • Dual GLP‑1/GIP agonists such as tirzepatide activate both receptors, providing stronger glycemic control and greater weight loss than GLP‑1‑only drugs.
  • Emerging data suggest possible cardiovascular, neuroprotective, and mental‑health benefits beyond the classic metabolic effects.

Practical Outcomes

  • Tirzepatide looks promising for aggressive weight‑loss and metabolic‑health experiments, but it still requires prescription and medical monitoring due to GI side effects and unknown long‑term safety. The review helps you understand the mechanistic advantage of adding GIP activation, so you can weigh it against the need for clinical supervision when designing personal protocols.

Summary

The review explains how drugs that mimic the gut hormones GLP‑1 and GIP (like tirzepatide) work to boost insulin, curb appetite, and slow stomach emptying, which helps lower blood sugar and cut weight. It also points out early signs that these drugs might protect the heart, brain, and mood. While the paper is a broad overview rather than a new experiment, it gives biohackers a clear picture of why dual‑acting drugs could be more powerful than GLP‑1‑only meds.

Abstract

This review provides a comprehensive examination of the clinical pharmacological mechanisms and broad therapeutic applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual receptor agonists targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. GLP-1RAs exert their effects by stimulating insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite through the activation of the GLP-1 receptor. These agents have demonstrated significant efficacy in the management of type 2 diabetes mellitus (T2DM) and obesity. Moreover, emerging evidence suggests that GLP-1RAs may confer cardiovascular protection, neuroprotective benefits, and positive effects on mental health. Dual GLP-1/GIP receptor agonists, such as tirzepatide, simultaneously activate both receptors, thereby potentiating glycemic control, promoting weight loss, and ameliorating metabolic dysfunction. This review also addresses recent advances in the development of other dual and triple receptor agonists. Distinct from prior reviews that predominantly focus on a single drug class or limited clinical indications, this article systematically contrasts the mechanistic pathways, therapeutic efficacy, and safety profiles of GLP-1RAs versus GLP-1/GIP dual receptor agonists. Notably, it integrates the most current evidence pertaining to novel domains, such as perioperative management, neuropsychiatric outcomes, and the innovation of multi-receptor agonists. This synthesis offers a timely and practical resource to inform clinical precision medicine and to guide future investigative efforts.

Study Information

Provider

pubmed

Year

2025

Date

2025-11-22T00:00:00.000Z

DOI

10.2147/dddt.s559919